Peter L. Garrambone, Jr.

While continuing to hold his seat as a member of the Board of Directors, Mr. Garrambone will assume the position of interim-CEO effective May 1, 2009.  Mr. Garrambone is a Business Development and Financial Executive, with a track record of success in corporate strategic planning, negotiating, and closing acquisitions and divestures that maximize value and grow the business. His experience includes operations, integration, financial planning and restructuring businesses to align with corporate vision and goals. He is recognized for maximizing returns and exceeding corporate objectives while remaining sensitive to human resource issues. He is skilled in managing business development and divestiture projects in the pharmaceutical, medical device, consumer healthcare and animal health arenas.

Most recently, Mr. Garrambone was Senior Vice President Business Development at Reliant Pharmaceuticals, Inc., acquired by GlaxoSmithKline in December 2007, where he was a member of the Executive Committee. He was hired in mid-2007 to lead business development, create a strategic plan for the company, and facilitate their IPO process. Prior to joining Reliant, Mr. Garrambone spent over 24 years driving change and executing growth and alignment strategies for Pfizer. During his tenure, he played key roles in both the Warner Lambert and Pharmacia acquisitions. He executed the company’s biotech acquisition strategy, successfully negotiating and closing six biotech acquisitions and numerous product rights’ transactions. In addition, he led the evaluation and divestiture execution of nine non-strategic businesses which realized over $27 Billion in proceeds. Most notably he played the leadership role in the sale of the Consumer Healthcare business to Johnson & Johnson for $16.6 Billion.

Mr. Garrambone holds an MBA from The Amos Tuck School at Dartmouth College with a concentration in Finance and General Management. Mr. Garrambone received his Bachelor of Arts degree in Mathematics and Economics from Colby College. He completed a number of Executive Programs at the University of Pennsylvania’s Wharton School and Northwestern University’s Kellogg School of Management.

William (Will) H. Lewis
Executive Vice President, Chief Financial Officer and Co-Founder

Will is Co-Founder, Executive Vice President and Chief Financial Officer of Aegerion.  Will has been involved in the operation, investing and banking of life sciences companies for more than ten years.  Will holds a BA Cum Laude from Oberlin College and a JD/MBA with Honors from Case Western Reserve University. Prior to attending graduate school he worked in the Foreign Service for the US Government.

William (Bill) J. Sasiela Ph.D.
Executive Vice President and Chief Medical Officer

Bill Sasiela joins Aegerion with long-standing research experience in lipid metabolism and atherosclerosis.  Bill has been in the pharmaceutical industry for nearly 10 years with Parke-Davis/Pfizer.  His initial role in the company was as a field Medical Liaison where he was involved in the launch of Lipitor and, in particular, was closely involved in the management of troglitazone (Rezulin).  Bill then joined the Lipitor Medical team first as a clinical director  and then later led all worldwide medical operations for Lipitor.

Finally, Bill was charged with building the Atherosclerosis Development team within Pfizer’s NY headquarters.  Within this role, he led the commercial development program for torcetrapib/atorvastatin as well as sat on the development teams for earlier development products such as ETC-216 (from Esperion). Additionally, he was actively involved in licensing activities for Pfizer within the atherosclerosis and metabolic areas and was part of the overall therapeutic area strategy team for Pfizer.

Bill joined Aegerion in December 2005. Bill has a B.S. in biochemistry from Virginia Tech and a Ph.D. from the University of South Carolina School of Medicine.  Bill also conducted post-doctoral research at the University of North Carolina, Chapel Hill.

Christine A. Pellizzari
Senior Vice President, General Counsel and Secretary

Christine Pellizzari was appointed Senior Vice President, General Counsel and Secretary in August 2007.  Prior to joining Aegerion, Ms. Pellizzari served as Senior Vice President, General Counsel and Secretary of Dendrite International, Inc., a provider of sales effectiveness, promotional and compliance solutions to the global pharmaceutical industry. Ms. Pellizzari joined Dendrite in 1998 and served as its General Counsel from 2000 to 2007. During her tenure, Ms. Pellizzari built and managed the company’s global legal organization and was responsible for legal, compliance and corporate secretarial functions worldwide. She was a member of the company's Executive Operations Management Committee and helped lead many critical initiatives, including the sale of the company to Cegedim S.A. in May, 2007.

Ms. Pellizzari joined Dendrite from the law firm of Wilentz, Goldman & Spitzer where she specialized in healthcare transactions. Before joining Wilentz, Ms. Pellizzari served as law clerk to the Honorable Reginald Stanton, Assignment Judge, Morris/Sussex Vicinage, Superior Court of New Jersey from 1994 to 1995. Ms. Pellizzari received her Bachelor of Arts degree from the University of Massachusetts in Amherst, MA and her Juris Doctorate from the University of Colorado School of Law in Boulder, CO.

Ms. Pellizzari was honored as a member of NJ Biz's "Forty under 40" in 2004. Her professional memberships and affiliations include the Association of Corporate Counsel, Society of Corporate Secretaries and Governance Professionals and the National Association of Stock Plan Professionals.